SCHEMBL4024477

SCHEMBL4024477

Cc1c(F)cccc1C1C(C(=O)c2cccc(O)c2)CN(CC(=O)N(C)C)CC1C(=O)c1cccc(O)c1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 1/20 0.37
EGFR P00533 1/20 0.37
LCK P06239 1/20 0.37
SRC P12931 1/20 0.37
ABL2 P42684 1/20 0.37
KIF11 P52732 5/20 0.34
KDM2B Q8NHM5 2/20 0.34
EED O75530 2/20 0.33
OPRM1 P35372 1/20 0.33
OPRD1 P41143 1/20 0.33
OPRK1 P41145 1/20 0.33
GRIN2B Q13224 2/20 0.33
GRIN1 Q05586 1/20 0.33
MGLL Q99685 1/20 0.33
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
SLC2A1 P11166 1/20 0.32
SLC2A4 P14672 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4024473 1.00 ABL1 (0.37) ABL1EGFRLCKSRCABL2
SCHEMBL4019756 0.90 GRIN2B (0.40) EEDGRIN2BGRIN1MEN1KMT2A
SCHEMBL4019761 0.90 GRIN2B (0.40) EEDGRIN2BGRIN1MEN1KMT2A
SCHEMBL4019987 0.90 KMT2A (0.39) EEDGRIN2BMEN1KMT2A
SCHEMBL4019982 0.90 KMT2A (0.39) EEDGRIN2BMEN1KMT2A
SCHEMBL4749448 0.89 EED (0.34) EEDOPRM1OPRD1OPRK1MEN1
SCHEMBL4019759 0.89 MEN1 (0.37) ABL1EGFRLCKSRCABL2
SCHEMBL4019762 0.89 MEN1 (0.37) ABL1EGFRLCKSRCABL2
SCHEMBL4024037 0.87 ALDH1A1 (0.37) MGLLMEN1KMT2A
SCHEMBL4024035 0.87 ALDH1A1 (0.37) MGLLMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7572814-B2 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds CYTOKINETICS, INCORPORATED (US) 2009-08-11 US claimed
US-20070161674-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2007-07-12 US claimed
US-7572814-B2 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds CYTOKINETICS, INCORPORATED (US) 2009-08-11 US disclosed
US-20070161674-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2007-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161674-A1 Certain chemical entities, compositions, and methods TP53, VHL, RB1 ABL1 549/4885EGFR 1673/4885LCK 1364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.